|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CNKSR2 |
Gene summary for CNKSR2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CNKSR2 | Gene ID | 22866 |
| Gene name | connector enhancer of kinase suppressor of Ras 2 | |
| Gene Alias | CNK2 | |
| Cytomap | Xp22.12 | |
| Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q8WXI2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 22866 | CNKSR2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 3.36e-04 | 1.89e-01 | -0.1808 |
| 22866 | CNKSR2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.89e-09 | 4.13e-01 | -0.0811 |
| 22866 | CNKSR2 | HTA11_78_2000001011 | Human | Colorectum | AD | 2.54e-03 | 2.54e-01 | -0.1088 |
| 22866 | CNKSR2 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.39e-09 | 2.57e-01 | -0.1954 |
| 22866 | CNKSR2 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.54e-05 | 1.93e-01 | -0.1464 |
| 22866 | CNKSR2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.04e-02 | 1.86e-01 | -0.059 |
| 22866 | CNKSR2 | HTA11_7862_2000001011 | Human | Colorectum | AD | 2.26e-03 | 3.13e-01 | -0.0179 |
| 22866 | CNKSR2 | HTA11_6818_2000001011 | Human | Colorectum | AD | 9.71e-08 | 4.64e-01 | 0.0112 |
| 22866 | CNKSR2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 7.83e-31 | 6.33e-01 | 0.294 |
| 22866 | CNKSR2 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.63e-07 | 2.90e-01 | 0.281 |
| 22866 | CNKSR2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 6.55e-05 | 1.25e-01 | 0.3005 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0099173 | Colorectum | AD | postsynapse organization | 51/3918 | 168/18723 | 2.47e-03 | 1.90e-02 | 51 |
| GO:0050808 | Colorectum | AD | synapse organization | 112/3918 | 426/18723 | 4.25e-03 | 2.92e-02 | 112 |
| GO:00991731 | Colorectum | SER | postsynapse organization | 46/2897 | 168/18723 | 5.20e-05 | 1.25e-03 | 46 |
| GO:00508081 | Colorectum | SER | synapse organization | 85/2897 | 426/18723 | 7.17e-03 | 4.99e-02 | 85 |
| GO:00991732 | Colorectum | MSS | postsynapse organization | 48/3467 | 168/18723 | 9.32e-04 | 9.44e-03 | 48 |
| GO:00508082 | Colorectum | MSS | synapse organization | 101/3467 | 426/18723 | 3.96e-03 | 2.89e-02 | 101 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CNKSR2 | SNV | Missense_Mutation | novel | c.673G>A | p.Glu225Lys | p.E225K | Q8WXI2 | protein_coding | deleterious(0) | benign(0.228) | TCGA-A2-A0SV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate therapy | zometa | PD |
| CNKSR2 | SNV | Missense_Mutation | c.380N>T | p.Ser127Leu | p.S127L | Q8WXI2 | protein_coding | deleterious(0) | benign(0.262) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CNKSR2 | SNV | Missense_Mutation | c.3049N>C | p.Asp1017His | p.D1017H | Q8WXI2 | protein_coding | tolerated(0.05) | benign(0.188) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CNKSR2 | SNV | Missense_Mutation | novel | c.77N>A | p.Cys26Tyr | p.C26Y | Q8WXI2 | protein_coding | deleterious(0) | probably_damaging(0.95) | TCGA-AC-A5XU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | SD |
| CNKSR2 | SNV | Missense_Mutation | novel | c.2021G>T | p.Arg674Ile | p.R674I | Q8WXI2 | protein_coding | tolerated(0.16) | possibly_damaging(0.584) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CNKSR2 | SNV | Missense_Mutation | novel | c.2226N>G | p.His742Gln | p.H742Q | Q8WXI2 | protein_coding | tolerated(0.34) | benign(0.021) | TCGA-AN-A0XU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CNKSR2 | SNV | Missense_Mutation | novel | c.2638N>A | p.Glu880Lys | p.E880K | Q8WXI2 | protein_coding | tolerated(0.35) | benign(0) | TCGA-AO-A0JC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
| CNKSR2 | SNV | Missense_Mutation | novel | c.1563N>T | p.Arg521Ser | p.R521S | Q8WXI2 | protein_coding | tolerated(0.34) | benign(0.039) | TCGA-BH-A5IZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| CNKSR2 | SNV | Missense_Mutation | c.2719N>C | p.Asp907His | p.D907H | Q8WXI2 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-E2-A1LL-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | docetaxel | PD | |
| CNKSR2 | SNV | Missense_Mutation | c.401N>A | p.Ala134Glu | p.A134E | Q8WXI2 | protein_coding | deleterious(0) | benign(0.1) | TCGA-E9-A1RC-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |